A Phase 2, Single-Dose, Randomized, Active and Placebo Controlled, Four-Period, Cross-Over Study of the Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 or Albuterol in Subjects With Persistent Asthma

• 1. Is a male or female subject between the ages of 12 and 65 years, inclusive.

• 2. Asthma that has been stable for at least four weeks prior to screening as defined by clinical history.

• 3. Reversible bronchoconstriction.

• 4. Has body weight more than 30 kilogram (kg) and body mass index between 18 and 34 kg/m², inclusive.

• 5. Has no medical history of hypertension and cardiovascular disease in the last 10 years.

• 6. At screening, has stable vital signs.